Assenagon Asset Management S.A. Sells 3,663 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Assenagon Asset Management S.A. lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 12.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,140 shares of the company’s stock after selling 3,663 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Neurocrine Biosciences were worth $3,568,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in NBIX. State Street Corp boosted its position in Neurocrine Biosciences by 11.7% in the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after purchasing an additional 539,936 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Neurocrine Biosciences by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,859,232 shares of the company’s stock worth $213,773,000 after purchasing an additional 39,610 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Neurocrine Biosciences by 23.0% in the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after buying an additional 228,444 shares during the last quarter. Braidwell LP grew its position in Neurocrine Biosciences by 20.9% during the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock valued at $105,734,000 after buying an additional 158,665 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Neurocrine Biosciences by 4.7% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 819,968 shares of the company’s stock valued at $94,478,000 after buying an additional 37,098 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX opened at $145.88 on Wednesday. The company has a market cap of $14.77 billion, a price-to-earnings ratio of 39.11 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The stock’s 50 day simple moving average is $132.17 and its two-hundred day simple moving average is $131.15.

Analysts Set New Price Targets

NBIX has been the subject of a number of recent research reports. Royal Bank of Canada cut their price objective on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. Barclays boosted their price objective on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday, December 23rd. Finally, Wedbush restated an “outperform” rating and set a $148.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $164.81.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kyle Gano sold 65,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the sale, the chief executive officer now directly owns 135,392 shares of the company’s stock, valued at $19,157,968. The trade was a 32.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now owns 15,449 shares in the company, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 68,694 shares of company stock valued at $9,676,730. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.